Patent · US Active

IL-17A inhibitors

US12252491B2 · kind B2 · utility

0Cited by
0References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 3, 2020
Grant dateMar 18, 2025
Priority date
Expiry dateJul 23, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.